Zapping lung nerves could ease heart Failure-Related high blood pressure

NCT ID NCT05824923

Ongoing Disease control Sponsor: Pulnovo Medical (Wuxi) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests a procedure called pulmonary arterial denervation (PADN) for people with heart failure who also have high blood pressure in the lungs. A special catheter delivers radiofrequency energy to nerves in the pulmonary artery, which may help lower pressure and improve heart function. The study includes 264 adults aged 18–75 with chronic heart failure and confirmed pulmonary hypertension. Researchers will track whether the procedure reduces hospitalizations, need for IV medications, or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a ring-shaped catheter that delivers radiofrequency energy to nerves in the pulmonary artery, a procedure called pulmonary arterial denervation (PADN)
What this could lead to: If successful, this procedure could offer a new treatment option for heart failure patients with pulmonary hypertension, potentially reducing hospitalizations and improving survival.
What could go wrong: This is an early-phase trial with 264 participants, so results may not apply to all patients. The procedure carries risks such as vessel damage, arrhythmia, or worsening heart failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates